4.3 Article

China's radiopharmaceuticals on expressway: 2014-2021

期刊

RADIOCHIMICA ACTA
卷 110, 期 6-9, 页码 765-784

出版社

WALTER DE GRUYTER GMBH
DOI: 10.1515/ract-2021-1137

关键词

China; nuclear medicine; positron emission tomography; radiopharmaceuticals; theranostics

资金

  1. Beijing Municipal Natural Science Foundation [Z200018]
  2. National Natural Science Foundation of China [U1867209, 21778003]
  3. Ministry of Science and Technology of the People's Republic of China [2017YFA0506300]
  4. Li Ge-Zhao Ning Life Science Youth Research Foundation [LGZNQN202004]
  5. China Postdoctoral Science Foundation [2020M680241]

向作者/读者索取更多资源

This review provides a comprehensive overview of the progress of radiopharmaceuticals in China in recent years, covering various areas such as brain imaging agents, cardiovascular imaging agents, infection and inflammation imaging agents, tumor radiopharmaceuticals, and boron delivery agents. The review highlights the advancements in radiopharmaceutical chemistry and discusses major events, clinical study status, and national regulatory support. The review concludes with a brief commentary on remaining limitations and emerging opportunities for China's radiopharmaceuticals.
This review provides an essential overview on the progress of rapidly-developing China's radiopharmaceuticals in recent years (2014-2021). Our discussion reflects on efforts to develop potential, preclinical, and in-clinical radiopharmaceuticals including the following areas: (1) brain imaging agents, (2) cardiovascular imaging agents, (3) infection and inflammation imaging agents, (4) tumor radiopharmaceuticals, and (5) boron delivery agents (a class of radiopharmaceutical prodrug) for neutron capture therapy. Especially, the progress in basic research, including new radiolabeling methodology, is highlighted from a standpoint of radiopharmaceutical chemistry. Meanwhile, we briefly reflect on the recent major events related to radiopharmaceuticals along with the distribution of major R&D forces (universities, institutions, facilities, and companies), clinical study status, and national regulatory supports. We conclude with a brief commentary on remaining limitations and emerging opportunities for China's radiopharmaceuticals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据